Journal - Current Computer-Aided Drug Design

Impact Factor

Current: 1.606
5 - Year: 1.156

Ranking & Category

57th of 59 in Chemistry, Medicinal
96th of 105 in Computer Science, Interdisciplinary Applications

Topic(s) Covered

2 Topic(s)

View

Aims & Scope

Current Computer-Aided Drug Design aims to publish all the latest developments in drug design based on computational techniques. The field of computer-aided drug design has had extensive impact in the area of drug design.

Current Computer-Aided Drug Design is an essential journal for all medicinal chemists who wish to be kept informed and up-to-date with all the latest and important developments in computer-aided methodologies and their applications in drug discovery. Each issue contains a series of timely, in-depth reviews, original research articles and letter articles written by leaders in the field, covering a range of computational techniques for drug design, screening, ADME studies, etc., providing excellent rationales for drug development.

Abstracted/Indexed in

Biochemistry & Biophysics Citation Index®, BIOSIS Previews, British Library, Cabell's Directory, Cambridge Scientific Abstracts (CSA)/ProQuest, Chemical Abstracts Service/SciFinder, ChemWeb, CNKI Scholar, Dimensions, EBSCO, EMBASE, Genamics JournalSeek, Google Scholar, InCites, Index Copernicus, J-Gate, Journal Citation Reports/Science Edition, JournalTOCs, MediaFinder®-Standard Periodical Directory, MEDLINE/PubMed, Open Abstracts (I4OA), PubsHub, QOAM, Science Citation Index Expanded™ (SciSearch®), Scilit, Scopus, Suweco CZ, TOC Premier, and Ulrich's Periodicals Directory.

Endorsement(s)

"The first issue of the journal Current Computer-Aided Drug Design is reflective of the course taken by the editor on the broadest possible coverage of the methodology development and applications of modern computational drug discovery. It is a must-read periodical for the professionals, educators and students interested in this important field."

Alexander Tropsha
Univ. of North Carolina, USA

Authors' Comments

It was a pleasure to work with Bentham Science Publishers.

Dr. Noelly Madeleine
(DSIMB, INSERM, U1134, Paris, F-75015, France and Université de la Réunion, UMR S 1134, Faculté des Sciences et Technologies, 15, avenue René Cassin, BP 7151, 97715 Saint Denis Messag Cedex 09, La Réunion, France)

Has contributed: Identification of Inhibitors for the Lutheran Blood Group Glycoprotein – Laminin 511/521 Interaction by Molecular Modeling and Simulation Techniques